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Abstract Aims/hypothesis: Loss of pancreatic beta cells
is the crucial event in the development of type 1 diabetes.
It is the result of an imbalance between autoimmune de-
struction and insufficient regeneration of islet cells. To study
the role of islet cell regeneration in the pathogenesis of type
1 diabetes, we focused on PAX4, a paired homeodomain
transcriptional repressor that is involved in islet cell growth.
Methods: The study included 379 diabetic children and
1,070 controls from two distinct populations, and a cohort
of children who had not developed type 1 diabetes, despite
the presence of islet cell antibodies. Genomic DNA analysis
of PAX4 was carried out via direct sequencing of PCR-
amplified fragments and allelic discrimination. We com-
pared the transrepression potential of the PAX4 variants in
βTC3 cells and analysed their influence on beta cell growth.
Results: The type 1 diabetic subjects are different from the
normal individuals in terms of the genotype distribution of
the A1168C single nucleotide polymorphism in PAX4. The
C/C genotype is frequent among type 1 diabetic children
(73%) and rare among the control population (32%). Con-
versely, the A/C genotype is prevalent among control sub-
jects (62%) and antibody-positive children without type 1
diabetes (73.6%), but uncommon among subjects with type
1 diabetes (17.5%). The combination of PAX4A and PAX4C
is functionally more active than PAX4C alone (the ‘diabetic’
variant). Beta cells expressing PAX4A and PAX4C efficient-
ly proliferate when stimulated with glucose, whereas cells
expressing the PAX4C variant alone do not. Conclusions/
interpretation: We have identified a link between beta cell
regenerative capacity and susceptibility to type 1 diabetes.
This finding could explain the fact that not all of the in-
dividuals who develop autoimmunity against beta cells ac-
tually contract the disease. TheC/C genotype of theA1168C
polymorphism in PAX4 can be viewed as a predisposition
marker that can help to detect individuals prone to develop
type 1 diabetes.
Keywords Diabetes mellitus, type 1 . Pancreas .
Regeneration
Abbreviations BrdU: 5-bromo-2′-deoxyuridine .
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Introduction
The central event in type 1 diabetes mellitus is the selective
loss of insulin-producing pancreatic beta cells. Type 1 dia-
betes can therefore be viewed as the result of an imbalance
between autoimmune beta cell destruction and beta cell re-
generation. Classically, the development of type 1 diabetes
is divided into different stages, from genetic predisposition,
to triggering, active autoimmunity and, finally, progressive
beta cell destruction [1]. The extensively documented poly-
genic inheritance pattern of type 1 diabetes suggests that
alterations in risk-modifying genes could lead to the even-
tual clinical manifestation of the disease. Specifically, al-
terations in these genes should play a role in the pathology
of the disease, i.e. beta cell destruction (primarily due to
immune mechanisms), decreased beta cell proliferation, and
insufficient insulin secretion in response to stimulators such
as glucose.
The mechanisms involved in the autoimmune destruc-
tion of beta cells have been extensively studied over the
past three decades [2, 3], whereas the factors involved in
islet cell development and regeneration have only recently
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been described and investigated (for reviews see [4, 5]).
Agents involved in organogenesis and differentiation of
the pancreas are also likely to be involved in the processes
of regeneration. Among these regulators, the transcription
factor Pax4 plays a crucial role in pancreatic beta cell
development. The Pax family of transcription factors con-
tain a paired box and a homeobox domain, and are essential
for the formation of several tissues present in all germ
layers in the mammalian embryo. Specifically, they are
involved in triggering the early events of cell differen-
tiation during organogenesis. The differentiation of endo-
derm-derived endocrine pancreas is mediated through Pax4
and Pax6 [6]. Inactivation of pax4 by homologous recom-
bination in mice results in the absence of mature insulin-
producing beta cells and somatostatin-producing delta cells,
and hyperplasia of glucagon-producing alpha cells [7]. The
main function of Pax4 is as a transcriptional repressor in
early pancreatic development [8, 9]. The mechanism by
which Pax4 influences beta cell function is not well un-
derstood. Activin A (a member of the TGF-β family) stim-
ulates Pax4 expression in pancreatic cell lines [10], and
simultaneously promotes the growth and differentiation of
human fetal pancreatic cells when combined with another
growth factor, betacellulin [11]. These findings indicate that
Pax4 is involved in the promotion of beta cell proliferation
by growth factors. Although initial investigations suggested
that PAX4 was not expressed in mature endocrine cells,
more recent studies have detected mRNA for the transcrip-
tion factor in adult human, rat and mouse pancreatic islets
[12–14]. We have previously demonstrated that low levels
of pax4 mRNA are expressed, and that production of these
transcripts is induced by the mitogens activin A and beta-
cellulin. Adenoviral-mediated overexpression of Pax4 in
islets was shown to produce a 3.5-fold increase in beta cell
proliferation [15]. A central concept that emerged from this
study is that Pax4 operates as a key regulator of adult beta
cell mass by converging the replicating effect of several
signal transduction pathways towards theMyc-Id2 cascade.
In parallel, cells protect themselves from c-Myc-induced
apoptosis by increasing Bcl-xL expression.
Genetic association studies in humans have reported an
association between PAX4 variants and type 2 diabetes [16,
17]; however, this does not appear to be a global phe-
nomenon, since it could not be found in other populations
[18]. The A1168C single nucleotide polymorphism (SNP)
we have examined has not been found to be linked to any
form of diabetes. In a study on Scandinavian families,
Holm et al. observed an association between type 1 dia-
betes and haplotypes at the PAX4 locus on chromosome
7q32 that, together with the ISL1 locus on chromosome
5q11–q13, constitutes a significant susceptibility factor for
type 1 diabetes [19].
We hypothesised that PAX4 will be ‘reactivated’ to pro-
mote the growth of islet cells in response to their de-
struction. If such a mechanism exists and is functional, the
pancreas would react to an immune attack by regenerating
beta cells. In contrast, inefficient proliferation would not be
able to counteract the ongoing destruction, eventually lead-
ing to type 1 diabetes. To gain insight into the possible role
of PAX4 in the pathogenesis of type 1 diabetes, we first
screened for mutations in PAX4 in children with type 1
diabetes, and then investigated the consequences of these
mutations in beta cell lines.
Subjects and methods
Subjects We initially recruited 249 children with type 1
diabetes (male:female ratio=0.53:0.47) and 424 normal
control subjects of Swiss origin (male:female=0.57:0.43),
and subsequently extended the analysis to include an ad-
ditional 130 diabetic subjects (male:female ratio=0.56:0.44)
and 646 normal control subjects (male:female ratio=0.63:
0.37) from a distinct German population. Type 1 diabetes
was diagnosed according to the criteria approved by the
American Diabetes Association [20]. All patients tested
positive for anti-islet cell antibodies. The control subjects
were unrelated individuals who did not have a history of
type 1 or type 2 diabetes in the first-degree family line. An
additional group included 19 school children (age 6–17
years) who, despite anti-islet cell antibody positivity, had
not developed diabetes within 16 years of follow-up [21].
Patients’ data and samples were anonymised according to
the Swiss law (SR 235.154 and 236.1), and their collection
conformed to the guidelines set out by the internal review
boards. All participants (or their parents) gave informed
consent. All samples were analysed in a blind fashion.
Genetic analysis Genomic DNA was extracted from pe-
ripheral blood leucocytes using the QIAGEN blood and
cell culture DNA kit (Hilden, Germany). PCR exonic am-
plification of PAX4 (accession no. CH236947.1) was per-
formed, and direct cycle sequencing of the PCR products
was carried out using the ABI Prism BigDye Terminators
v.3 kit and an ABI Prism 310 Genetic Analyzer (Applied
Biosystems, Rotkreuz, Switzerland). Allelic discrimina-
tion was performed using two different methods: (1) RFLP
based on HphI digestion (performed according to the man-
ufacturer’s instructions; New England Biolabs, Allschwil,
Switzerland); and (2) an allelic discrimination assay using
specific TaqMan MGB probes, with the results analysed on
the ABI Prism 7,700 Sequence Detection System (Applied
Biosystems; the sequences of the primers and probes used
are available upon request). To further confirm the data, 20
samples per group per genotype were sequenced as men-
tioned above. Primer sequences and PCR conditions are
available upon request (all primers were supplied byMycro-
synth, Balgach, Switzerland). Chi square, significance and
relative risk were calculated using standard methods.
Expression studies To study the functional implications of
the PAX4 variants, we developed an RT-PCR method us-
ing PAX4 mRNA ectopically expressed in peripheral blood
leucocytes of normal subjects who were homozygous for
either the A or C variant [22]. The two PAX4 cDNAvariants
were ligated into a pCMV-Script vector (Stratagene, Basel,
Switzerland) and used for functional studies. Mouse βTC3
(German Collection of Microorganism and Cell Cultures,
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Braunschweig, Germany),αTC1.9 and NIH3T3 (American
Type Culture Collection, Manassas, VA, USA) cells were
cultured (7.5×103 cells) in regular DMEM medium (25
mmol/l glucose; Life Technologies, Basel, Switzerland). As
they reached 80% confluence (at 36 h), the cells were tran-
siently transfected with PAX4A, PAX4C or a combination of
the two at a 1:1molar ratio, using 50μg of lipofectamine per
10 μg of DNA per 60-mm plate (Life Technologies). We
used a construct containing promoter sequences of the
rat insulin I gene (−410 bp) cloned upstream of a firefly
lucierfase cDNA (pFOXluc-410RIP1) as a reporter, and
the control plasmid pFOXluc1 (which is devoid of the tar-
get sequence). Both plasmids were generous gifts from
M. German (University of California, San Francisco, CA,
USA). To normalise for transfection efficiency, the con-
stitutively active Renilla luciferase-containing pRL-SV40
vector (Promega, Wallisellen, Switzerland) was used in ad-
dition to pFOXluc-410RIP1. Luciferase activity was mea-
sured 48 h after transfection using the Dual-Luciferase
Reporter Assay System (Promega) as suggested by the sup-
plier. All results are expressed as luciferase activity relative
to control (where no PAX4=1). Total protein content was
measured using the Bio-Rad Protein Assay (Hercules, CA,
USA).
To study the influence of the PAX4 variants on cell
growth, 7.5×103 βTC3, αTC1.9 and NIH3T3 cells were
seeded on 35-mm plates. Cells were then transfected with
PAX4A, PAX4C, a combination of the two at a molar ratio
of 1:1, or empty vector. The transfection efficiency, which
was assessed using a β-galactosidase-containing vector
(SV-40 β-gal; Promega), ranged from 40 to 60%. At 48 h
after transfection, the cells were cultivated for 12 h in the
absence of glucose, and then exposed different concentra-
tions of glucose (0, 5, 15, 25 and 30 mmol/l) for 12 h,
harvested, and counted in triplicate. To study the mecha-
nism of putative changes in cell number, we used the same
experimental design together with a commercial kit for
analysis of proliferation, as directed by the supplier (Cell
Proliferation ELISA, BrdU; Roche Applied Science).
Briefly, the assay is based on the detection of 5-bromo-
2′-deoxyuridine (BrdU), an analogue of thymidine. Cells
are labelled by the addition of BrdU for 4 h. During this
labelling period, BrdU is incorporated into the DNA of
cycling cells in place of thymidine. After the removal of the
labelling medium, an anti-BrdU antibody that binds to the
BrdU incorporated into the newly synthesised DNA is
added. The immune complexes are detected by the sub-
sequent substrate reaction. The reaction product is quan-
tified by measuring the absorbance using a scanning
spectrophotometer (ELISA reader).
Electrophoresis mobility shift assay Nuclear extracts were
obtained from transfected βTC3 cells (48 h after trans-
fection) as previously described [23]. The double-stranded
oligonucleotides C2 (Top strand: 5′-AGCTGTGAGCAGG
GACAGGTCTGGC-3′) and DH1 (Top strand: 5′-AGCTG
TGAGCAGGGACAGGTCTGGCCACCGGGCCCCTG-
3′) [24] of the human insulin promoter, which are known
to be target sequences for PAX4 were end-labelled with
[γ32-P]-ATP using T4 polynucleotide kinase. Binding as-
says were performed as previously described [23].
Results
Genetic findings The SNP in which an A or a C may be
present in exon 9 of PAX4 (cDNA residue 1168; Table 1),
corresponding to a proline or a histidine residue at position
321 in PAX4 protein, respectively (P321H), was differ-
entially distributed between control subjects and subjects
with type 1 diabetes. As shown in Table 1, 63.5 and 61.4%
of normal Swiss and German individuals, respectively,
were heterozygous, whereas 76.7 and 71.5% of the Swiss
and German type 1 diabetic subjects, respectively, carried
the C/C genotype. Remarkably, 73% of children who had
an anti-beta cell autoimmune reaction (islet cell antibody-
positive) and carried the A/C genotype still remain free of
type 1 diabetes after 16 years of follow-up (Table 1). The
relative risk of developing type 1 diabetes for carriers of
the C/C genotype is 3.75-fold higher than for individuals
carrying the A/C or A/A genotype. Subjects with the A/C
genotype have a five-fold lower chance of developing type
1 diabetes when compared with individuals carrying the
other genotypes. In agreementwith previous reports [18], no
association was found between the A1168C SNP (P321H)
and type 2 diabetes (n=344, data not shown).
Functional implications To investigate potential functional
differences between the PAX4 variants, we tested their
transrepression potential in beta-like (βTC3), alpha-like
(αTC1.9) and non-islet cells (NIH3T3). Compared with
the A variant, the PAX4C ‘diabetic’ variant was less ef-
fective at repressing the transcription of target sequences
in insulinoma βTC3 cells. A combination of the two var-
iants—a situation mimicking the control genotype—pro-
Table 1 Genotype frequencies of the A1168C SNP in the study
population
Subjects Genotype
C/Ca A/Cb A/A
Swiss sample
Type 1 diabetic subjects (n=249) 76.7 15.2 7.9
Control subjects (n=424) 31.2 63.5 5.3
χ2=252.1, df=4, p<0.0001
German sample
Type 1 diabetic subjects (n=130) 71.53 20 8.5
Control subjects (n=646) 33.9 61.46 4.64
χ2=245.1, df=4, p<0.0001
Antibody-positive
Type 1 diabetes-negative subjects (n=19) 10.5 73.6 15.9
χ2=260, df=2, p<0.0001
df degrees of freedom
aRelative risk of developing type 1 diabetes in carriers of the C/C
genotype vs other genotypes=3.75 (strong risk)
bRelative risk of developing type 1 diabetes in carriers of the A/C
genotype vs other genotypes=0.18 (strong protection)
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duced the greatest level of repression (Fig. 1). This effect
appears to be pancreas-specific, since similar results were
obtained in αTC1.9 cells but not in NIH3T3 cells (not
shown). Compared with PAX4A, PAX4C appears to have
an impaired ability to bind DNA target sequences (Fig. 2),
even though the polymorphism may not be located within
the DNA-binding domains. The combination of the A and
the C variants appears to increase the DNA binding ca-
pacity of PAX4 (Fig. 2).
If PAX4 variants play a role in the pathogenesis of type 1
diabetes, they may influence beta cell number and/or their
differentiation. The cell count was increased by a factor
of 2.5 at higher glucose concentrations (15–25 mmol/l)
compared with that at lower concentrations (0 or 5 mmol/l)
(Fig. 3a). No further increase in the number of βTC3 cells
was seen at 30 mmol/l glucose (data not shown). The
glucose-dependent increase in cell number was blunted in
cells transfected with PAX4C, and this effect appeared to be
overcome by the combination of A and C. The effect of
transfection with PAX4A on the glucose-dependent increase
in the number of βTC3 cells was not the same as that
produced by transfection with the combination of PAX4A
and PAX4C (Fig. 3a). The glucose-driven influence of
PAX4 on cell number appears to be beta cell specific, as
transfection with the PAX4 variants did not affect the cell
count of αTC1.9 cells or non-islet NIH3T3 cells (data not
shown). The incorporation of BrdU into the newly syn-
thesised DNA of replicating cells was significantly lower
in PAX4C-transfected βTC3 cells than in cells express-
ing PAX4A either alone or in combination with PAX4C
(Fig. 3b). These results are consistent with those of the
cell count experiments. The data suggest that the PAX4C
‘diabetic’ variant limits the proliferation of beta cells under
glucose stimulation, the main physiological regulator of
beta cell growth [21]. The addition of the A to the C variant
(the control), restores the proliferation potential of these
cells. The results indicate that the observed effects are
mainly due to the overexpressed human PAX4 rather than
the endogenous mouse Pax4 that is present in βTC3 cells,
since the outcomes of all functional studies were more sig-
nificant in the presence of human PAX4 than in its absence.
Discussion
In the present study we have demonstrated that there are
differences between patients with type 1 diabetes and nor-
mal individuals in terms of the genotype distribution of
the A1168C SNP in PAX4. The differences were extremely
striking: the majority of normal individuals were hetero-
zygous, whereas most of the diabetic patients were homozy-
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Fig. 1 Transcriptional activity of variants of
human PAX4 in transfected βTC3 cells. Rat
insulin I promoter sequences (−410 bp) were
cloned upstream of a firefly luciferase cDNA
(pFOXluc-410RIP1) and transfected into βTC3
cells, together with PAX4C, PAX4A or a 1:1
mixture of the two. The same construct devoid of
the target sequence was used as a control
(pFOXluc). A constitutively active Renilla lucif-
erase-containing construct (pRL-SV40) was used
for standardisation purposes. As a control for
background luminescence, the Renilla luciferase-
containing vector was transfected with or without
PAX4A and PAX4C. The data are expressed as
relative luciferase activity (firefly/Renilla)
(where no PAX4=1). The results were subjected
to statistical analysis (paired t-test). The data
represent the means±SD of at least three inde-
pendent experiments. *p<0.05; **p<0.02;
***p<0.002; ****p<0.001. Firefly, pFOXluc;
Renilla, pRL-SV40; RIP, pFOXluc-410RIP1
Fig. 2 The binding of the PAX4 variants to the human insulin
promoter was analysed using an electrophoretic mobility shift assay.
The oligonucleotides C2 and DH1 (corresponding to PAX4 target
sequences on the human insulin promoter) were incubated with
extracts from βTC3 cells transfected with PAX4A and PAX4C, either
alone or in combination at different molar ratios. The resultant
protein–DNA complexes were visualised by electrophoresis
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gous for the C allele. The same results were demonstrated
in two distinct populations, thus rendering a bias in the
choice of the cohort less likely. The fact that a significant
association between PAX4 haplotypes and diabetes was
recently described in a family-based Scandinavian study
indicates that this is not an isolated phenomenon [19]. To
investigate possible functional differences between the two
variants, we tested their DNA binding capacity and trans-
repression potential. It appears that the PAX4C ‘diabetic’
variant is less active than the PAX4A variant in terms of
binding and repressing target sequences. Transcription is
repressed to the greatest extent when the two variants are
combined (the situation mimicking the normal genotype).
Although PAX4A seems to be the main regulator in alpha-
like cells, its role in beta cell function is at present unclear.
The combination of the two variants seems to slightly
increase their DNA binding capacity, which may explain
the apparent heterozygote advantage. The basis of such
phenomenon is at present unclear, since members of the Pax
family of transcription factors are not known to form dimers.
If PAX4 variants play a role in the pathogenesis of type 1
diabetes, they may influence the proliferation and/or dif-
ferentiation of beta cells. The PAX4C ‘diabetic’ variant
limits the proliferation of beta cells under glucose stimu-
lation, the main physiological regulatory mechanism of
beta cell growth [25]. The addition of the A variant to the C
variant restores the proliferation potential of these cells.
These data provide evidence for the loss of function of the
‘diabetic’ genotype (C/C) and the protective function of the
‘control’ genotype (A/C).
One of the implications that can be drawn from this
study concerns possible preventive approaches for type 1
diabetes. Although the clinical onset of type 1 diabetes is
acute, beta cell damage precedes clinical diabetes by sev-
eral months or years. Two large randomised trials that
aimed to control the destruction of beta cells have, un-
fortunately, yielded negative results. The Diabetes Preven-
tion Trial-1 (DPT-1) failed to show any protective effect of
insulin treatment [26], and in the European Nicotinamide
Diabetes Intervention Trial (ENDIT), the administration of
nicotinamide, which was hypothesised to attenuate DNA
and beta cell damage, did not have any effect [27]. If beta
cells cannot be protected from destruction, their regener-
ation potential could be used to counteract the ongoing
attack. This seems to be achievable in the mature pancreas,
since differentiated beta cells have been shown to have
significant proliferative potential in vivo [28]. Further stud-
ies are required to improve our understanding of factors
that predispose or protect against diabetes. This would
allow the development of new assays that could be used in
combination with those for previously identified markers in
order to identify susceptible individuals. Our results in-
dicate that the C/C genotype of the A1168C polymorphism
in PAX4 is a diabetes susceptibility factor and might be
used to detect individuals prone to develop type 1 diabetes.
On the basis of our results we conclude that the com-
bination of the two PAX4 variants may be involved in a
process that has a protective effect against the onset of type
1 diabetes. This hypothesis is supported by the intriguing
fact that children who tested positive for antibodies to beta
cells and carried the A/C genotype did not develop type 1
diabetes. Our results indicate a link between beta cell
regenerative capacity and susceptibility to type 1 diabetes,
which could explain the fact that only a certain proportion
of individuals who develop autoimmunity against beta
cells actually contract the disease.
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Fig. 3 a Effect of the overexpression of the PAX4 variants on βTC3
cell number in the presence of increasing concentrations of glucose.
The results were subjected to statistical analysis (paired t-test).
*p<0.05; **p<0.02; ***p<0.01. The data represent the means±SD
of at least three independent experiments. b Effect of the expression
of the PAX4 variants on the proliferation of transfected βTC3 cells,
as measured by BrdU Cell Proliferation ELISA. The graph shows
the incorporation of BrdU in adherent βTC3 cells transfected with
PAX4A, PAX4C, neither, or a combination of the two and cultured in
96-well microtitre plates under different concentrations of glucose
(0–25 mmol/l). The rate of proliferation at higher glucose con-
centrations (30 mmol/l) is comparable to that at 25 mmol/l. The data
represent duplicate measurements of experiments performed in
triplicate. The results were subjected to statistical analysis (paired
t-test paired). *p<0.05; **p<0.02; ***p<0.01. Blank, horizontal
stripes; no PAX4, black fill; PAX4A, dotted fill; PAX4C, diagonal
stripes; combination of PAX4A and PAX4C, white fill
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